Stocks
Funds
Screener
Sectors
Watchlists
BLCM

BLCM - Bellicum Pharmaceuticals Inc Stock Price, Fair Value and News

$0.07 
Market Closed

BLCM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLCM Price Action

BLCM RSI Chart

BLCM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLCM Valuation

BLCM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BLCM Fundamentals

BLCM Revenue

BLCM Earnings

BLCM Profitability

BLCM Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20225.0M3.9M2.7M1.5M
202113.7M11.2M8.7M6.2M
202018.7M0016.2M
20191.5M2.5M2.3M7.1M
20181.0M1.1M1.1M1.1M
2017738.0K809.0K869.0K1.1M
2016402.0K554.0K721.0K768.0K
20151.3M865.5K262.5K282.0K
20141.9M1.9M1.8M1.8M
20130001.9M
BLCM
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
 WEBSITEbellicum.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13